Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
The DOI matches its Crossref record, with a small difference in title or year; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Background: Several pharmacologic options for type 2 diabetes are available. Purpose: To compare benefits and harms of glucose-lowering drugs in adults with type 2 diabetes. Data Sources: Several databases from inception through 18 December 2019 and ClinicalTrials.gov on 10 April 2020. Study Selection: English-language randomized trials that had at least 24 weeks of intervention and assessed the effects of glucose-lowering drugs on mortality, glycemic, and vascular outcomes. Data Extraction: Pairs of reviewers extracted data and appraised risk of bias. Data Synthesis: 453 trials assessing 21 antidiabetic interventions from 9 drug classes were included. Interventions included monotherapies (134 trials), add-on to metformin-based therapies (296 trials), and monotherapies versus add-on to metformin therapies (23 trials). There were no differences between treatments in drug-naive patients at low cardiovascular risk. Insulin regimens and specific glucagon-like peptide-1 receptor agonists (GLP-1 RAs) added to metformin-based background therapy produced the greatest reductions in hemoglobin A1c level. In patients at low cardiovascular risk receiving metformin-based background treatment (298 trials), there were no clinically meaningful differences between treatments for mortality and vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background treatment (21 trials), oral semaglutide, empagliflozin, liraglutide, extended-release exenatide, and dapagliflozin reduced all-cause mortality. Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular death. Odds of stroke were lower with subcutaneous semaglutide and dulaglutide. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduced heart failure hospitalization and end-stage renal disease. Subcutaneous semaglutide and canagliflozin increased diabetic retinopathy and amputation, respectively. Limitation: Inconsistent definitions of cardiovascular risk and low-level confidence in some estimates for patients at low cardiovascular risk. Conclusion: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. Primary Funding Source: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a network meta-analysis of 453 trials assessing glucose-lowering medications from nine drug classes, the greatest reductions in HbA1c were seen with insulin regimens and GLP-1 RA (223).”
In the citing paper
“However, the comparative effectiveness of the two drug classes has been assessed in three recent network meta-analyses, which found that, in people with type 2 diabetes, SGLT2i were superior to GLP-1 RA in reducing HHF and a composite kidney outcome, while GLP-1 RA seemed more ef fi cacious in reducing the risk of stroke (223,259,260).”
In the citing paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
In the citing paper
“In a large systemic review and network analysis, including several GLP-1RAs, subcutaneous semaglutide was the only glucose-lowering drug for which this signal was observed”
From Safety of Semaglutide (2021) · cites this paper as [120]
In the citing paper
“A systematic review and meta-analysis of CGM use in adults with type 2 diabetes (12 randomized clinical trials with 1248 participants taking insulin, GLP-1RA, or oral glucose-lowering medications) reported that CGM led to a mean difference in HbA1C reduction over 10 to 34 weeks of −0.31% (95% CI, −0.43% to −0.19%) compared with BGM.49”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [49]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 1×
“ods (9), and report detailed methods in section 1 of the Supplement (available at Annals.”
MethodDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“On the basis of pairwise meta-analyses of cardiovascular outcome trials, compared with placebo, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce cardiovascular death and stroke (4), whereas sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce heart failure hospitalization (5) and end-stage renal disea…”
BackgroundChecking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“We evaluated consistency in the networks both locally by comparing direct with indirect evidence (19) and globally by using the design-by-treatment interaction model (20).”
MethodConsistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“We evaluated consistency in the networks both locally by comparing direct with indirect evidence (19) and globally by using the design-by-treatment interaction model (20).”
MethodOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935
Research works printed but not linked: 1
- Schwarzer G, 2007, R news, 7, 40
Cited by
Items 101–200 of 401
GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects
Cardoso, P., Dennis, J., & Pearson, E. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194742 · Cited by 20
Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
Lunder, M., Janić, M., & Šabović, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062796 · Cited by 20
Metformin—mechanisms of its glycemia-reducing effect
Drewe, J., Foretz, M., & Krähenbühl, S. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100106 · Cited by 19
Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis
Shah, R. H., Vedantam, S., Kumar, S., Amin, S., Pearlman, M. Y., & Bhalla, S. (2023) · Obesity Surgery · doi:10.1007/s11695-022-06437-7 · Cited by 19
Ma, K., Zhou, L., Zhang, Y., Zhao, J., Yao, C., Tian, C., & Li, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1134297 · Cited by 19
Patoulias, D., Koufakis, T., Ruža, I., El‐Tanani, M., & Rizzo, M. (2024) · Pragmatic and Observational Research · doi:10.2147/por.s471476 · Cited by 19
Gomes, D., Presume, J., Gonçalves, P. D. A., Almeida, M., Mendes, M., & Ferreira, J. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07547-3 · Cited by 18
Pinto, M., Brennan, L., Diehl, K., Lin, S., & Heacock, S. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241289959 · Cited by 18
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes
Bolli, G. B., Home, P. D., Porcellati, F., Riddle, M. C., Gerstein, H. C., Lucidi, P., Fanelli, C. G., & Owens, D. R. (2025) · Diabetes Care · doi:10.2337/dci24-0104 · Cited by 19
Zheng, H., Sigal, R. J., Coyle, D., Bai, Z., Johnston, A., Elliott, J., Hsieh, S., Kelly, S., Chen, L., Skidmore, B., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3515 · Cited by 18
Wu, S., He, Y., Wu, Y., Ji, Y., Hou, L., Liu, X., Ge, Y., Yu, Y., Yu, Y., Wei, Y., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.897776 · Cited by 18
Lin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., Chiang, F., & Tu, Y. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad078 · Cited by 18
Furusawa, S., Nomoto, H., Oba‐Yamamoto, C., Takeuchi, J., Ito, M., Kurihara, H., Aoki, S., Miya, A., Kameda, H., Nakamura, A., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0648 · Cited by 18
Exosome-like Nanoparticles Extracted from Plant Cells for Diabetes Therapy
Xiao, X., Guo, Y., Msomi, N. Z., Islam, M. S., & Chu, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189155 · Cited by 17
Concepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., Yovera, J. G. G., Ruvalcaba-Barbosa, G. Y., Cura-Rodríguez, L. D., González-Rodríguez, J. S., Urteaga, L. A. C., Pérez-Reyes, A. I., Aldave, J. E. Q., & Paz‐Ibarra, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.111435 · Cited by 17
Chang, Z., Xu, J., Qin, Y., Zheng, Q., Zhao, L., Wang, Y., & Zhang, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282143 · Cited by 17
Fatima, H., Rangwala, H. S., Mustafa, M. S., Shafique, M. A., Abbas, S. R., Rizwan, A., Ahmad, T. K. F., & Arshad, A. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s439587 · Cited by 17
Schmidt, D. W., Argyropoulos, C., & Singh, N. (2021) · Kidney360 · doi:10.34067/kid.0000622021 · Cited by 17
Hao, Z., Xiao, H., Shao, H., & Feng, H. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4126995 · Cited by 17
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
Scheen, A. J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2210673 · Cited by 17
Lin, D. S., Lo, H., Huang, K., Lin, T., Lee, J., & Lin, L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15788 · Cited by 16
“28 In our cohort, patients were followed for a mean of approximately 1 year after propensity score matching, a time window in which early worsening of retinopathy may occur.”
Management of Diabetic Wounds: Expert Panel Consensus Statement
Hsia, H. C., Eriksson, E. K., Gurtner, G. C., Veves, A., Hamdy, O., Margolis, D. J., Armstrong, D. G., Lavery, L. A., Grice, E., Schultz, G., et al. (2025) · Advances in Wound Care · doi:10.1177/21621918251366586 · Cited by 16
Kuang, L., Li, W., Xu, G., You, M. S., Wu, W., & Li, C. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-2944 · Cited by 16
Cases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 16
SGLT2 Inhibitors and Peripheral Vascular Events
Marchiori, E., Rodionov, R. N., Peters, F., Magnussen, C., Nordanstig, J., Gombert, A., Spanos, K. T., Jarzebska, N., & Behrendt, C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.001 · Cited by 16
Metformin: still the sweet spot for CV protection in diabetes?
Rena, G., Mordi, I. R., & Lang, C. C. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.10.018 · Cited by 16
Ferrara, F., Zovi, A., Langella, R., Cavallaro, F., Nava, E., Trama, U., & Vitiello, A. (2023) · International Journal of Healthcare Management · doi:10.1080/20479700.2023.2210393 · Cited by 15
SABOURET, P., BOCCHINO, P. P., ANGELINI, F., D’ASCENZO, F., GALATI, G., FYSEKIDIS, M., DE FERRARI, G. M., FISCHMAN, D. L., BHATT, D. L., & BIONDI-ZOCCAI, G. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.05900-2 · Cited by 14
Malandris, K., Papandreou, S., Avgerinos, I., Karagiannis, T., Paschos, P., Michailidis, T., Liakos, A., Bekiari, E., Sinakos, E., & Τσάπας, Α. (2023) · HORMONES · doi:10.1007/s42000-023-00493-z · Cited by 14
Self-citationApproach to the Patient With Type 2 Diabetes Requiring Add-On Medication
Baum, H. B. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae056 · Cited by 14
Fano, M. D., Falorni, A., Malara, M., Porcellati, F., & Fanelli, C. G. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s466328 · Cited by 14
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 14
Bagepally, B. S., Chaikledkaew, U., Youngkong, S., Anothaisintawee, T., Thavorncharoensap, M., Dejthevaporn, C., & Thakkinstian, A. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s328433 · Cited by 14
Hirose, N., Tsujimoto, N., Katayose, T., & Chin, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14600 · Cited by 14
Oh, S., Purja, S., Shin, H., Kim, M., & Kim, E. Y. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221106866 · Cited by 14
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · Cardiology Research · doi:10.14740/cr1459 · Cited by 14
Valenta, S. T., Stecchi, M., Perazza, F., Nuccitelli, C., Villanova, N., Pironi, L., Atti, A. R., & Petroni, M. L. (2023) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-023-01625-5 · Cited by 14
Klonoff, D. C., Levy, B. L., Jaasma, M. J., Bharara, M., Edgar, D. R., Nasr, C. E., Caraway, D. L., Petersen, E., & Armstrong, D. G. (2024) · Journal of Pain Research · doi:10.2147/jpr.s463383 · Cited by 14
Review Article: The Flagship of Evidence-Based Medicine
Lazarides, M. K., Lazaridou, I.-Z., & Παπάνας, Ν. (2021) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734621995636 · Cited by 14
Bradley, C. L., McMillin, S. M., Hwang, A. Y., & Sherrill, C. H. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221134127 · Cited by 13
Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
Lau, D., & Gamble, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15459 · Cited by 14
SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes
Jensen, S. K., Heide‐Jørgensen, U., Andersen, I. T., Bonnesen, K., Fu, E. L., Thomsen, R. W., & Christiansen, C. F. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.7409 · Cited by 13
Dinesh, S., Sharma, S., & Chourasiya, R. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230505140206 · Cited by 13
Kuß, O., Opitz, M. E., Brandstetter, L. V., Schlesinger, S., Roden, M., & Hoyer, A. (2023) · Diabetologia · doi:10.1007/s00125-023-05951-2 · Cited by 13
Management of type 2 diabetes in the new era
Liakos, A., Karagiannis, T., Avgerinos, I., Malandris, K., Τσάπας, Α., & Bekiari, E. (2023) · HORMONES · doi:10.1007/s42000-023-00488-w · Cited by 13
Self-citationKoufakis, T., Παπάνας, Ν., Zebekakis, P. E., & Kotsa, K. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1942843 · Cited by 13
Zhang, Q., Zhang, Q., Li, X., Du, G., Feng, X., Ding, R., Chi, Y., & Liu, Y. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13538 · Cited by 12
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 12
Self-citationBedtime Prediction of Nocturnal Hypoglycemia in Insulin-Treated Type 2 Diabetes Patients
Kronborg, T., Hangaard, S., Hejlesen, O. K., Vestergaard, P., & Jensen, M. H. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221141736 · Cited by 12
Al‐Saleh, Y., Busaidi, N. A., Dahi, W. A. A., Almajnoni, M., Mohammed, A. S., Alshali, K. Z., Alshamiri, M. Q., Sifri, S. A., Arafah, M., Chan, S. P., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02529-7 · Cited by 12
Chu, L., Bradley, R. M., Auerbach, P., & Abitbol, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15834 · Cited by 12
Adjunctive therapies in type 1 diabetes mellitus
Lane, K. L., & Freeby, M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000602 · Cited by 12
Lyu, B., Grams, M. E., Chang, A. R., Inker, L. A., Coresh, J., & Shin, J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.11.013 · Cited by 12
Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
González-Clemente, J. M., García-Castillo, M., Martínez, J. J. G., Jiménez, A., Llorente, I., Matute, E., Pérez, C. T., Izarra, A., & Lecube, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01280-6 · Cited by 12
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
Xu, J., Yao, D., & Xia, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13398 · Cited by 11
Development of a liquid crystal-based α-glucosidase assay to detect anti-diabetic drugs
Sun, H., Yin, F., Liu, X., Jiang, T., Ma, Y., Gao, G., Shi, J., & Hu, Q. (2021) · Microchemical Journal · doi:10.1016/j.microc.2021.106323 · Cited by 11
Bayram, Y. E., & Eskan, M. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284319 · Cited by 11
Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
Bellido, V., Martínez, J., Calvo, F. L., Villarroel, A., Lecumberri, E., Moreno, J., Morillas, C., Rodrigo, S., Izarra, A., & Lecube, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01237-9 · Cited by 11
Koufakis, T., Zografou, I., Doumas, M. N., & Kotsa, K. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00610-8 · Cited by 10
Salamah, H. M., Marey, A., Elsayed, E., Hasan, M. T., Mahmoud, A., Abualkhair, K. A., Abo‐elnour, D. E., Abdelhaleem, I. A., & Abd‐ElGawad, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-46274-x · Cited by 10
Chandra, G., Lavikainen, P., Siirtola, P., Tamminen, S., Ihalapathirana, A., Laatikainen, T. K., Martikainen, J. A., & Röning, J. (2025) · Clinical Epidemiology · doi:10.2147/clep.s505966 · Cited by 10
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
Tsapas, A., Karagiannis, T., Avgerinos, I., Matthews, D. R., & Bekiari, E. (2021) · Annals of Internal Medicine · doi:10.7326/l20-1278 · Cited by 10
Self-citationChen, C., Peng, H., Li, M., Lu, X., Huang, M., Zeng, Y., & Dong, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.664533 · Cited by 10
López‐Cano, C., Santos, M. D., Sánchez, E., Martí, R., Bueno, M., Gutiérrez-Carrasquilla, L., & Lecube, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-07250-z · Cited by 10
Gu, S., Hu, X., Zhen, X., Shi, L., Shao, H., Sun, X., Gu, Y., Huang, M., & Dong, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185435 · Cited by 10
Moke, E. G., Omogbai, E. K. I., Osagie-Eweka, S. E., Uchendu, A. P., Obayuwana, M. O., Okoro-Akpandu, E., & Ben‐Azu, B. (2023) · Laboratory Animal Research · doi:10.1186/s42826-023-00159-2 · Cited by 10
Deng, Y., Polley, E. C., Wallach, J. D., Herrin, J. S., Ross, J. S., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000419 · Cited by 10
Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis
Qiu, M., Ding, L., Zhang, M., & Zhou, H. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107803 · Cited by 10
Hu, S., Su, X., Deng, X., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.701446 · Cited by 10
Chenchula, S., Varthya, S. B., & Padmavathi, R. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210910165402 · Cited by 10
Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons
Koufakis, T., Popovic, D. S., & Παπάνας, Ν. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2237414 · Cited by 10
Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf301 · Cited by 9
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 9
Choi, J. H., Kang, S., Kim, S., Kim, W. J., Kim, J. M., Bae, J., Yun, J., Jeon, E. J., Kim, Y., Bae, J. H., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0978 · Cited by 9
Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
Heller, S. R., Raposo, J. F., Tofé, S., Hanif, W., Schroner, Z., Down, S., & Blevins, T. (2022) · Clinical Diabetes · doi:10.2337/cd22-0016 · Cited by 9
Salis, F., Cossu, E., & Mandas, A. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02135-y · Cited by 9
Kidneys in heart failure: Impact of flozins
Stompór, T. P., & Winiarska, A. (2023) · Kardiologia Polska · doi:10.33963/v.kp.97844 · Cited by 9
Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations
Adeniji, O. A., Olowoyo, P., Akinyemi, R., Fisher, M., & Owolabi, M. O. (2024) · Stroke · doi:10.1161/strokeaha.123.044231 · Cited by 9
GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study
Tentolouris, A., Ntanasis‐Stathopoulos, I., Filippatos, C., Terpos, E., Kastritis, E., Duque, E. R., Dimopoulos, M. A., Gavriatopoulou, M., & Briasoulis, Α. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70140 · Cited by 8
Insulin resistance and type 2 diabetes as allostatic responses to chronic nutrient excess
Prentki, M., Nolan, C. J., James, D. E., Thorens, B., Rhodes, C. J., Corkey, B. E., Ling, C., Froguel, P., Mathieu, C., Gautier, J., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.06.012 · Cited by 8
Chandra, V., Yadav, P., & Raghuvanshi, V. (2023) · Journal of Pharmaceutical Research · doi:10.33140/jpr.08.02.14 · Cited by 8
Medical Management of Obesity: Current Trends and Future Perspectives
Calderón, A., Aguilera-Astudillo, M., Rojas, A. P., Dowlatshahi, S., Kansara, A., Shakil, J., & Patham, B. (2025) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1503 · Cited by 8
Promising measures to reduce the mortality in Russia: an analytical review
Kobyakova, О. S., Стародубов, В. И., Khaltourina, D. A., Zykov, V. A., Zubkova, T. S., & Замятнина, Е. С. (2021) · Health Care of the Russian Federation · doi:10.47470/0044-197x-2021-65-6-573-580 · Cited by 8
Avgerinos, I., Karagiannis, T., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15200 · Cited by 8
Self-citationSullivan, S. D., Wouters, O. J., Cousin, E. M., Kirihennedige, A. S., & Hernandez, I. (2024) · Value in Health · doi:10.1016/j.jval.2024.08.001 · Cited by 7
Jiang, F., Wu, B., Qin, Z., Xie, Y., Na, Y., Chen, W., & Xu, H. (2024) · American Journal of Translational Research · doi:10.62347/eshe6987 · Cited by 7
Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.
Thomas, T. S., & Srinivasa, S. (2024) · PubMed Central · Cited by 7
Bonora, B. M., Giaccari, A., Consoli, A., Broglio, F., Avogaro, A., Fadini, G. P., & for the GLIMPLES Study Investigators (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70045 · Cited by 7
Bae, J. H., Choe, H. J., Yang, Y., Seo, M. H., Choi, J. H., Kim, G., Lyu, Y. S., Han, J. H., Kang, S., Kim, W. J., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0739 · Cited by 7
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
Mardare, I., Campbell, S., Meyer, J. C., Sefah, I. A., Massele, A. Y., & Godman, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794363 · Cited by 7
Hu, S., Wang, S., Qi, C., Gu, S., Shi, C., Mao, L., & Fan, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.831364 · Cited by 7
Jin, B.-Y., Song, J., Kim, J. Y., Park, J.-H., Kim, S. J., Cho, H., Moon, S., Kim, D.-H., & Ahn, S. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2022.154171 · Cited by 7
Vargas, K. G., Rütten, T., Siemes, B., Brockmeyer, M., Parco, C., Hoss, A., Schlesinger, S., Jung, C., Roden, M., Kelm, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15519 · Cited by 7
Palecek, E. J., Kimzey, M. M., Zhang, J., Marsden, J. E., Bays, C., Moran, W. P., Mauldin, P. D., & Schreiner, A. D. (2024) · Journal of Investigative Medicine · doi:10.1177/10815589241270427 · Cited by 7
Rasalam, R. R., Abdo, S., Deed, G., O’Brien, R. C., & Overland, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14953 · Cited by 7
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Kataria, A., & Argyropoulos, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_25 · Cited by 7
Hisada, H., Tsuji, Y., Kubota, D., Miura, Y., Mizutani, H., Ohki, D., Yakabi, S., Takeuchi, C., Kakushima, N., Yamamichi, N., et al. (2025) · Digestive Endoscopy · doi:10.1111/den.70016 · Cited by 6
Metadata
- Authors
- Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E.
- Affiliations
- Clinical Research and Evidence-Based Medicine Unit and Diabetes Centre, Aristotle University of Thessaloniki, Thessaloniki, Greece, and Harris Manchester College, University of Oxford, Oxford, United Kingdom (A.T.)
- Aristotle University of Thessaloniki (GR)
- Churchill Hospital (GB)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-08-18
- Volume
- 173
- Issue
- 4
- Pages
- 278-286
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3037508799
- Cited by
- 346
- References
- 34
- Citations by year
- 2026: 31 · 2025: 62 · 2024: 75 · 2023: 67 · 2022: 51 · 2021: 50 · 2020: 10
- FWCI
- 33.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Foundation for the Study of Diabetes (PAtient-Centred Treatment to support a holistic approach towards type 2 diabetes (PACT) Programme supported by an unrestricted educational grant from AstraZeneca)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, antidiabetic drugs, comparative effectiveness, metformin, GLP-1 receptor agonists, SGLT2 inhibitors, semaglutide, empagliflozin, liraglutide, dapagliflozin, canagliflozin, insulin, cardiovascular risk, all-cause mortality, cardiovascular mortality, stroke, heart failure hospitalization, end-stage renal disease, diabetic retinopathy, amputation, glycemic control, HbA1c, vascular outcomes, risk of bias
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.